New drug combo shows promise in slowing pancreatic cancer
NCT ID NCT04887805
First seen Nov 19, 2025 · Last updated Jun 19, 2026 · Updated 29 times
Summary
This study tests whether a combination of two drugs, lenvatinib and pembrolizumab, can help keep advanced pancreatic cancer from getting worse. The trial involves 28 adults whose cancer cannot be removed by surgery and who have already responded to initial treatment. The goal is to see if this maintenance therapy can extend the time before the cancer progresses.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED PANCREATIC DUCTAL ADENOCARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.